PMGC Holdings Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $30.3M
- Price
- $6.66
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.18%
- Volume
- 204.0K
About
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Quick stats
Shares outstanding4.5M
Computed float454.4K
Float / shares10.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840563
Websitehttps://pmgcholdings.com
AI Summary
AI-generated1/43
minorbullishoperations update
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings (ELAB), filed two U.S. patent applications for its preclinical assets EL-22 and EL-32, targeting microgravity-induced muscle loss during spaceflight.
The filings aim to broaden the IP portfolio for myostatin and activin A inhibition, extending beyond terrestrial weight loss applications to the emerging space health market.
NorthStrive emphasized that there are no current agreements with NASA or commercial space operators, and the filing of a patent application does not guarantee issuance or commercial success.
Red flags
- Assets are preclinical
- No agreements or contracts with NASA or commercial space operators
- Patent application does not guarantee issuance or commercial protection